- Home
- MURA vs FTHM Comparison
MURA vs FTHM Comparison
Compare MURA & FTHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MURA
- FTHM
- Stock Information
- Founded
- MURA 2013
- FTHM 2010
- Country
- MURA Ireland
- FTHM United States
- Employees
- MURA N/A
- FTHM N/A
- Industry
- MURA
- FTHM Real Estate
- Sector
- MURA
- FTHM Finance
- Exchange
- MURA Nasdaq
- FTHM Nasdaq
- Market Cap
- MURA 35.7M
- FTHM 38.3M
- IPO Year
- MURA N/A
- FTHM 2020
- Fundamental
- Price
- MURA $2.08
- FTHM $2.63
- Analyst Decision
- MURA Strong Buy
- FTHM
- Analyst Count
- MURA 3
- FTHM 0
- Target Price
- MURA $12.00
- FTHM N/A
- AVG Volume (30 Days)
- MURA 465.5K
- FTHM 1.6M
- Earning Date
- MURA 11-12-2025
- FTHM 11-06-2025
- Dividend Yield
- MURA N/A
- FTHM N/A
- EPS Growth
- MURA N/A
- FTHM N/A
- EPS
- MURA N/A
- FTHM N/A
- Revenue
- MURA N/A
- FTHM $390,032,000.00
- Revenue This Year
- MURA N/A
- FTHM $25.22
- Revenue Next Year
- MURA N/A
- FTHM $16.19
- P/E Ratio
- MURA N/A
- FTHM N/A
- Revenue Growth
- MURA N/A
- FTHM 19.16
- 52 Week Low
- MURA $0.95
- FTHM $0.65
- 52 Week High
- MURA $4.74
- FTHM $3.37
- Technical
- Relative Strength Index (RSI)
- MURA 52.70
- FTHM 64.22
- Support Level
- MURA $2.05
- FTHM $1.80
- Resistance Level
- MURA $2.09
- FTHM $3.09
- Average True Range (ATR)
- MURA 0.01
- FTHM 0.39
- MACD
- MURA 0.01
- FTHM 0.07
- Stochastic Oscillator
- MURA 66.67
- FTHM 55.05
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
About FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service (SaaS) offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. Majority of revenue is from Real Estate segment.